Skip to main content
Premium Trial:

Request an Annual Quote

If Biogen Says No, Mr. Icahn, GTO Would Take $23 Billion

If you remember anyone who used to say that biotech would never amount to anything, now's the time to make the told-you-so phone call. Biogen Idec says it is considering a possible sale of the company, and one of the interested parties is Carl Icahn, who offered at least $23 billion, according to this article in the Wall Street Journal. Biogen Idec has a market cap of about $23.5 billion.

 

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.